These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 21046988)

  • 1. Assessment of protective role of polyherbal preparation, Livina, against anti-tubercular drug induced liver dysfunction.
    Gulati K; Ray A; Vijayan VK
    Indian J Exp Biol; 2010 Mar; 48(3):318-22. PubMed ID: 21046988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels.
    Jeong I; Park JS; Cho YJ; Yoon HI; Song J; Lee CT; Lee JH
    J Korean Med Sci; 2015 Feb; 30(2):167-72. PubMed ID: 25653488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity.
    Baniasadi S; Eftekhari P; Tabarsi P; Fahimi F; Raoufy MR; Masjedi MR; Velayati AA
    Eur J Gastroenterol Hepatol; 2010 Oct; 22(10):1235-8. PubMed ID: 20461008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of hepatotoxicity due to anti tuberculosis treatment: a novel integrative approach.
    Adhvaryu MR; Reddy N; Vakharia BC
    World J Gastroenterol; 2008 Aug; 14(30):4753-62. PubMed ID: 18720535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pattern of adverse drug reactions experienced by tuberculosis patients in a tertiary care teaching hospital in Western Nepal.
    P V K; Palaian S; Ojha P; P R S
    Pak J Pharm Sci; 2008 Jan; 21(1):51-6. PubMed ID: 18166520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.
    Yee D; Valiquette C; Pelletier M; Parisien I; Rocher I; Menzies D
    Am J Respir Crit Care Med; 2003 Jun; 167(11):1472-7. PubMed ID: 12569078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Secular increase in the incidence rate of drug-induced hepatitis due to anti-tuberculosis chemotherapy including isoniazid and rifampicin].
    Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H; Mohri M
    Kekkaku; 2003 Apr; 78(4):339-46. PubMed ID: 12739393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tubercular therapy (ATT) induced thrombocytopenia: A systematic review.
    Kaur A; Bhandari RK; Rohilla R; Shafiq N; Prakash G; Mothsara C; Pandey AK; Malhotra S
    Indian J Tuberc; 2023 Oct; 70(4):489-496. PubMed ID: 37968056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Liver toxicity of combined rifampicin-isoniazid-ethambutol medication (author's transl)].
    Austerhoff A; Kindler U; Knop P; Knieriem HJ
    Dtsch Med Wochenschr; 1974 May; 99(22):1182 p. PubMed ID: 4835559
    [No Abstract]   [Full Text] [Related]  

  • 11. [Fulminant hepatitis in the course of antitubercular treatment (apropos of 2 cases)].
    Mbaye PS; Talarmin F; Sane M; Eladari D; Klotz F
    Dakar Med; 1995; 40(2):129-31. PubMed ID: 9827070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Classification of liver incidents occurring during antitubercular treatments which include rifampicin].
    Blanchon P; Paillas J; Groseille Y; Holler A; Blanchon F
    Ann Med Interne (Paris); 1974 Dec; 125(12):919-22. PubMed ID: 4469954
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of two pulmonary tuberculosis drug treatments and acetylator status on liver function in a Zimbabwean population.
    Neill P; Pringle D; Mhonda M; Kusema T; Nhachi CF
    Cent Afr J Med; 1990 Apr; 36(4):104-7. PubMed ID: 2225025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens.
    Ho CC; Chen YC; Hu FC; Yu CJ; Yang PC; Luh KT
    Clin Infect Dis; 2009 Jun; 48(11):1526-33. PubMed ID: 19400686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rifampicin and ethambutol in retreatment of chronic pulmonary tuberculosis.
    Wiman LG; Johansson R; Tegner KB
    Scand J Respir Dis; 1973; 54(5):255-63. PubMed ID: 4777378
    [No Abstract]   [Full Text] [Related]  

  • 16. [Evaluation of hepatic function in new cases of pulmonary tuberculosis due to the use of standard chemotherapy regimens I and IIB].
    Abdullaev RIu; Vaniev EV; Kaminskaia GO; Vasil'eva IA; Komissarova OG
    Probl Tuberk Bolezn Legk; 2009; (2):57-61. PubMed ID: 19382645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of cavitary and infiltrating pulmonary tuberculosis with and without the immunomodulator Dzherelo.
    Zaitzeva SI; Matveeva SL; Gerasimova TG; Pashkov YN; Butov DA; Pylypchuk VS; Frolov VM; Kutsyna GA
    Clin Microbiol Infect; 2009 Dec; 15(12):1154-62. PubMed ID: 19456829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatoprotective activity of Moringa oleifera on antitubercular drug-induced liver damage in rats.
    Pari L; Kumar NA
    J Med Food; 2002; 5(3):171-7. PubMed ID: 12495589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Rifampicin. Study of its antitubercular effect and its hepatic tolerance in 200 patients].
    Macquet V; Lafitte P; Rogeaux Y
    Lille Med; 1972 May; 17(5):755-61. PubMed ID: 5056293
    [No Abstract]   [Full Text] [Related]  

  • 20. [Hepatic functional changes induced by the combined use of isoniazid, pyrazinamide and rifampicin in the treatment of pulmonary tuberculosis].
    de Souza AF; de Oliveira e Silva A; Baldi J; de Souza TN; Rizzo PM
    Arq Gastroenterol; 1996; 33(4):194-200. PubMed ID: 9302332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.